Inovio Net Debt from 2010 to 2024

INO Stock

USD 4.07 0.01 0.25%

Inovio Pharmaceuticals Net Debt yearly trend continues to be very stable with very little volatility. Net Debt is likely to grow to about 16.7 M this year. Net Debt is the total debt of Inovio Pharmaceuticals minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1998-12-31

Previous Quarter

-21.4 M

Current Value

-9.2 B

Quarterly Volatility

905.2 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Inovio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inovio Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 1.2 M or Total Revenue of 790.4 K, as well as many indicators such as Price To Sales Ratio of 155, Dividend Yield of 1.0E-4 or PTB Ratio of 1.1. Inovio financial statements analysis is a perfect complement when working with Inovio Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

Latest Inovio Pharmaceuticals' Net Debt Growth Pattern

Below is the plot of the Net Debt of Inovio Pharmaceuticals over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Inovio Pharmaceuticals' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inovio Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Inovio Net Debt Regression Statistics

	Arithmetic Mean	(25,450,733)
	Geometric Mean	25,423,869
	Coefficient Of Variation	(237.67)
	Mean Deviation	33,925,708
	Median	(19,136,472)
	Standard Deviation	60,487,798
	Sample Variance	3658.8T
	Range	289M
	R-Value	0.01
	Mean Square Error	3939.5T
	R-Squared	0.0002
	Significance	0.96
	Slope	179,719
	Total Sum of Squares	51222.8T

Inovio Net Debt History

	2024	16.7 M
	2023	15.9 M
	2022	-14.3 M
	2021	-38.1 M
	2020	-211.7 M
	2019	77.3 M
	2018	-23.7 M

Other Fundumenentals of Inovio Pharmaceuticals

Net Debt To E B I T D A

Inovio Pharmaceuticals Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Long Term Debt	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Investments	Good Will	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt Total	Short Long Term Debt
Total Assets		0.97	-0.62	-0.53	0.59	0.75	0.63	1.0	-0.36	0.08	-0.11	-0.32	0.57	-0.05	0.88	0.26	0.92	0.57	-0.41	-0.46	0.87	0.88	0.72	-0.68	0.11
Total Stockholder Equity	0.97		-0.75	-0.43	0.48	0.74	0.42	0.97	-0.31	-0.08	-0.08	-0.27	0.49	-0.01	0.83	0.23	0.96	0.51	-0.34	-0.39	0.91	0.91	0.66	-0.65	0.1
Net Debt	-0.62	-0.75		-0.07	0.11	-0.66	0.07	-0.61	0.02	0.26	0.17	0.09	-0.1	-0.09	-0.26	-0.31	-0.67	-0.04	0.1	0.09	-0.7	-0.65	-0.42	0.24	-0.26
Retained Earnings	-0.53	-0.43	-0.07		-0.52	-0.25	-0.59	-0.55	0.55	-0.24	-0.26	0.36	-0.38	0.32	-0.67	0.47	-0.59	-0.98	0.46	0.72	-0.43	-0.48	-0.15	0.9	0.63
Accounts Payable	0.59	0.48	0.11	-0.52		0.27	0.65	0.6	-0.33	0.25	-0.11	-0.2	0.61	-0.13	0.84	0.23	0.43	0.48	-0.3	-0.35	0.37	0.42	0.66	-0.45	0.11
Net Receivables	0.75	0.74	-0.66	-0.25	0.27		0.41	0.73	-0.08	-0.08	0.14	-0.25	0.39	0.39	0.53	0.32	0.68	0.3	-0.32	-0.05	0.62	0.61	0.54	-0.38	0.17
Total Liab	0.63	0.42	0.07	-0.59	0.65	0.41		0.61	-0.38	0.55	-0.16	-0.34	0.58	-0.15	0.65	0.24	0.38	0.51	-0.45	-0.47	0.32	0.38	0.57	-0.46	0.1
Total Current Assets	1.0	0.97	-0.61	-0.55	0.6	0.73	0.61		-0.41	0.05	-0.12	-0.28	0.54	-0.08	0.9	0.21	0.93	0.6	-0.38	-0.48	0.88	0.9	0.73	-0.71	0.09
Intangible Assets	-0.36	-0.31	0.02	0.55	-0.33	-0.08	-0.38	-0.41		-0.22	0.14	-0.4	-0.21	0.3	-0.45	0.49	-0.42	-0.61	0.16	0.54	-0.35	-0.39	-0.19	0.6	0.34
Long Term Debt	0.08	-0.08	0.26	-0.24	0.25	-0.08	0.55	0.05	-0.22		-0.32	-0.16	0.51	-0.31	0.07	0.11	-0.11	0.16	-0.26	-0.39	-0.16	-0.13	0.03	-0.01	0.04
Short Term Debt	-0.11	-0.08	0.17	-0.26	-0.11	0.14	-0.16	-0.12	0.14	-0.32		-0.28	0.22	0.38	0.02	-0.39	0.06	0.26	-0.23	0.19	-0.17	-0.18	-0.52	-0.09	-0.51
Common Stock	-0.32	-0.27	0.09	0.36	-0.2	-0.25	-0.34	-0.28	-0.4	-0.16	-0.28		-0.33	-0.14	-0.29	-0.31	-0.24	-0.27	0.68	0.02	-0.11	-0.12	-0.06	0.19	0.1
Property Plant Equipment	0.57	0.49	-0.1	-0.38	0.61	0.39	0.58	0.54	-0.21	0.51	0.22	-0.33		-0.04	0.63	0.25	0.44	0.36	-0.47	-0.3	0.26	0.28	0.29	-0.23	0.11
Current Deferred Revenue	-0.05	-0.01	-0.09	0.32	-0.13	0.39	-0.15	-0.08	0.3	-0.31	0.38	-0.14	-0.04		-0.07	0.24	-0.06	-0.31	-0.13	0.82	-0.22	-0.24	-0.13	0.37	0.19
Short Term Investments	0.88	0.83	-0.26	-0.67	0.84	0.53	0.65	0.9	-0.45	0.07	0.02	-0.29	0.63	-0.07		0.09	0.83	0.69	-0.4	-0.45	0.71	0.74	0.65	-0.73	-0.02
Good Will	0.26	0.23	-0.31	0.47	0.23	0.32	0.24	0.21	0.49	0.11	-0.39	-0.31	0.25	0.24	0.09		-0.04	-0.53	-0.13	0.35	0.05	0.04	0.6	0.45	0.86
Net Tangible Assets	0.92	0.96	-0.67	-0.59	0.43	0.68	0.38	0.93	-0.42	-0.11	0.06	-0.24	0.44	-0.06	0.83	-0.04		0.68	-0.36	-0.48	0.89	0.9	0.5	-0.79	-0.12
Capital Surpluse	0.57	0.51	-0.04	-0.98	0.48	0.3	0.51	0.6	-0.61	0.16	0.26	-0.27	0.36	-0.31	0.69	-0.53	0.68		-0.41	-0.73	0.54	0.58	0.15	-0.95	-0.66
Deferred Long Term Liab	-0.41	-0.34	0.1	0.46	-0.3	-0.32	-0.45	-0.38	0.16	-0.26	-0.23	0.68	-0.47	-0.13	-0.4	-0.13	-0.36	-0.41		0.07	-0.18	-0.2	-0.1	0.3	0.16
Long Term Investments	-0.46	-0.39	0.09	0.72	-0.35	-0.05	-0.47	-0.48	0.54	-0.39	0.19	0.02	-0.3	0.82	-0.45	0.35	-0.48	-0.73	0.07		-0.51	-0.55	-0.27	0.76	0.38
Net Invested Capital	0.87	0.91	-0.7	-0.43	0.37	0.62	0.32	0.88	-0.35	-0.16	-0.17	-0.11	0.26	-0.22	0.71	0.05	0.89	0.54	-0.18	-0.51		1.0	0.6	-0.73	-0.07
Net Working Capital	0.88	0.91	-0.65	-0.48	0.42	0.61	0.38	0.9	-0.39	-0.13	-0.18	-0.12	0.28	-0.24	0.74	0.04	0.9	0.58	-0.2	-0.55	1.0		0.62	-0.76	-0.09
Capital Stock	0.72	0.66	-0.42	-0.15	0.66	0.54	0.57	0.73	-0.19	0.03	-0.52	-0.06	0.29	-0.13	0.65	0.6	0.5	0.15	-0.1	-0.27	0.6	0.62		-0.31	0.55
Long Term Debt Total	-0.68	-0.65	0.24	0.9	-0.45	-0.38	-0.46	-0.71	0.6	-0.01	-0.09	0.19	-0.23	0.37	-0.73	0.45	-0.79	-0.95	0.3	0.76	-0.73	-0.76	-0.31		0.54
Short Long Term Debt	0.11	0.1	-0.26	0.63	0.11	0.17	0.1	0.09	0.34	0.04	-0.51	0.1	0.11	0.19	-0.02	0.86	-0.12	-0.66	0.16	0.38	-0.07	-0.09	0.55	0.54

Click cells to compare fundamentals

About Inovio Pharmaceuticals Financial Statements

Inovio Pharmaceuticals investors utilize fundamental indicators, such as Net Debt, to predict how Inovio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	15.9 M	16.7 M
Net Debt To EBITDA	(0.12)	(0.12)

When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock:

How To Invest In Inovio

Details

Is Inovio Stock a good investment?

Details

What is Inovio Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.43)

Revenue Per Share

0.025

Quarterly Revenue Growth

(0.55)

Return On Assets

(0.40)

Return On Equity

(0.91)

The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inovio Net Debt from 2010 to 2024

Latest Inovio Pharmaceuticals' Net Debt Growth Pattern

Inovio Net Debt Regression Statistics

Inovio Net Debt History

Other Fundumenentals of Inovio Pharmaceuticals

Inovio Pharmaceuticals Net Debt component correlations

About Inovio Pharmaceuticals Financial Statements

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY